Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors

HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive tumor growth and poor prognosis. Targeting the ERBB2 pathway with single-agent therapies has shown limited efficacy due to resistance mechanisms and the complexity of gene i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2024-12, Vol.25 (23), p.12840
Hauptverfasser:	Rojas-Salazar, Yareli, Gómez-Montañez, Emiliano, Rojas-Salazar, Jorge, de Anda-Jáuregui, Guillermo, Hernández-Lemus, Enrique
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antimitotic agents Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer therapies Development and progression Disease Drug resistance Drug Synergism Drug therapy, Combination Drugs Erlotinib Hydrochloride - pharmacology Female Gene amplification Gene Expression Regulation, Neoplastic - drug effects Gene Regulatory Networks - drug effects Glioma Humans Kidney cancer Kinases Lapatinib - pharmacology Lung cancer Medical prognosis Metabolism Protein Kinase Inhibitors - pharmacology Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Signal Transduction - drug effects Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!